Fractyl Health, Inc. (NASDAQ:GUTS) Shares Shorted: Short Interest Up 120.4% in October

Fractyl Health, Inc. (NASDAQ:GUTS – Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 30th, there was short interest totaling 585,071 shares, a growth of 120.4% from the October 15th total of 265,423 shares. Based on an average daily trading volume, of 1,925,065 shares, the short-interest ratio is currently 0.3 days. Approximately 4.8% of the company’s shares are sold short.

Fractyl Health Stock Performance

Shares of Fractyl Health stock opened at $0.90 on Monday. The business has a 50-day simple moving average of $3.89 and a 200 day simple moving average of $6.87. Fractyl Health has a one year low of $0.80 and a one year high of $29.34. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.98 and a quick ratio of 1.98. The firm has a market capitalization of $11.98 million, a price-to-earnings ratio of -0.29 and a beta of 2.91.

Fractyl Health (NASDAQ:GUTS – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($1.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.50) by $0.43. On average, research analysts anticipate that Fractyl Health will post -5.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

GUTS has been the topic of several recent analyst reports. Craig Hallum set a $5.00 target price on shares of Fractyl Health in a report on Monday, October 19th. Wall Street Zen downgraded Fractyl Health from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings downgraded Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 3rd. Finally, Morgan Stanley lowered their price objective on Fractyl Health to $4.00 and set an “equal weight” rating for the company in a research report on Monday, October 19th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Fractyl Health currently has a consensus rating of “Hold” and a consensus price target of $50.25.

Read Our Latest Research Report on Fractyl Health

Hedge Funds Weigh In On Fractyl Health

Institutional investors have recently modified their holdings of the company. Nantahala Capital Management LLC bought a new position in shares of Fractyl Health in the 2nd quarter worth $8,968,058. Bank of America Corp DE acquired a new stake in Fractyl Health in the 2nd quarter valued at $4,791,000. Pale Fire Capital SE grew its position in Fractyl Health by 84.5% in the 1st quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock valued at $2,711,000 after purchasing an additional 2,711,103 shares during the period. General Catalyst Group Management LLC bought a new stake in Fractyl Health during the 2nd quarter valued at $3,880,000. Finally, BlackRock Inc. bought a new stake in Fractyl Health during the 2nd quarter valued at $1,431,000.

Fractyl Health Company Profile

(Get Free Report)

Fractyl Health is a clinical-stage therapeutics company focused on developing treatments for metabolic diseases, including type 2 diabetes and obesity. The company is based in Burlington, Massachusetts. Its lead program, Revita, is an investigational endoscopic procedure designed to resurface the lining of the duodenum, the first part of the small intestine. Fractyl is studying whether this approach can improve metabolic function and provide lasting benefits for people with type 2 diabetes. The company is also developing Rejuva, an experimental gene therapy platform intended to address obesity and related metabolic conditions.

See Also

Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.